Trial Profile
A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Nov 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 12 Oct 2022 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.
- 12 Aug 2022 Planned End Date changed from 1 Jun 2023 to 30 Jun 2023.